Drugs Made In America Acquisition Corp. Ordinary Shares
NASDAQ:DMAAShell Companies
+$0.00 today
- Market cap
- $264.62M
- Beta
- 0.00
- P/E (TTM)
- 36.7
- EPS (TTM)
- $0.29
Volume 0.00M
Average 0.11M
DMAA Net Income
Bottom-line profit after all expenses, interest, and taxes.
Drugs Made In America Acquisition Corp. Ordinary SharesNASDAQ: DMAA
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income grows, but more slowly than its trailing trend
Q1 FY2026 net income of $1.97M rose 57.1% year over year, behind the +500.1% change in trailing-twelve-month net income. Sequentially, it rose 825.3% from the prior quarter.
What to watch
Whether quarterly growth recovers from +57.1% toward the trailing-twelve-month pace of +500.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Net Income history
USD · from the income statement
- Latest · FY2025
- 5.94M USD
- Year-over-year change
- +1240317.7%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.94M | +1240317.7% |
| FY2024 | 2024-12-31 | (479) | — |
Net Income vs competitors
How DMAA compares with its peers on the latest reported figures
- DMAA's LTM Mar 2026 net income of $6.66M is the 9th highest of the 10 companies compared; the peer median is $8.51M.
- Its year-over-year change of +500.1% is the 2nd highest of 5, against a peer median of +124.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
TACOUBerto Acquisition Corp. Unit | LTM Mar 2026 | $10.11M | — | — | — |
| LTM Mar 2026 | $10.11M | — | — | — | |
TACHTitan Acquisition Corp. | LTM Mar 2026 | $9.08M | +3583382.5% | — | — |
| LTM Mar 2026 | $8.6M | +22.8% | — | — | |
| LTM Mar 2026 | $8.51M | -21.1% | — | — | |
| LTM Mar 2026 | $7.99M | +227.0% | +2.1% | — | |
OYSEOyster Enterprises II Acquisition Corp | LTM Mar 2026 | $7.9M | — | — | — |
| LTM Mar 2026 | $6.86M | — | — | — | |
| LTM Mar 2026 | $6.66M | +500.1% | — | — | |
| LTM Mar 2026 | -$10.32M | — | — | — | |
| Peer median (excluding DMAA) | $8.51M | +124.9% | +2.1% | — | |
Competitors are the stored peer set for DMAA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | 0 | 0 |
| Gross Profit | 0 | 0 |
| Gross Margin | — | — |
| Research & Development | 0 | 0 |
| Selling, General & Admin | 480 | 2.82M |
| Operating Expenses | 480 | 2.82M |
| Depreciation & Amortization | 480 | 0 |
| EBITDA | (279.85K) | (2.82M) |
| EBITDA Margin | — | — |
| Operating Income | (479) | (2.82M) |
| Operating Margin | — | — |
| Interest Income | 0 | 8.76M |
| Interest Expense | 0 | 0 |
| Other Income / Expenses | 0 | 8.76M |
| Income Before Tax | (479) | 5.94M |
| Pre-Tax Margin | — | — |
| Income Tax Expense | 0 | 0 |
| Net Income | (479) | 5.94M |
| Net Margin | — | — |
| EPS (Basic) | (0.06) | 0.19 |
| EPS (Diluted) | (0.06) | 0.19 |
| Weighted Avg Shares | 8.57M | 21.01M |
| Weighted Avg Shares (Diluted) | 8.57M | 21.01M |
Drugs Made In America Acquisition Corp. Ordinary Shares
NASDAQ:DMAA
Intrinsic Alpha fair value
Locked
Current Price
$10.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.